{"commentary":{"count":23,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":13,"x_thread":6,"podcast":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06376526\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"IMMUNOPLANT","nct_id":"NCT06376526","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=immunoplant-nct06376526. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"IMMUNOPLANT","arms":[{"description":"Participants in this group will be administered a fixed duration of Linvoseltamab for four to six 28-day cycles, depending on minimal residual disease (MRD) conversion status. After four cycles, participants that are MRD-negative will no longer receive study treatment. Participants that are MRD-positive will receive an additional two cycles of Linvoseltamab.\n\nTotal participation duration is up to 3 years.","label":"Linvoseltamab Group","type":"EXPERIMENTAL"}],"collaborators":["Regeneron Pharmaceuticals"],"completion_date":{"date":"2029-08-31","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":150,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Linvoseltamab","type":"BIOLOGICAL"}],"last_update":"2026-08-18","lead_sponsor":"Dickran Kazandjian, MD","official_title":"Immuno-consolidation for Newly Diagnosed Multiple Myeloma Using Lack of MRD Negativity After Initial cOmbination Therapy to Pursue Deeper Responses With Linvoseltamab ANd Delay Transplant","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-08-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Minimal Residual Disease (MRD) Negativity Rate","timeFrame":"Up to 6 months"}],"references":[],"start_date":{"date":"2024-08-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"IMMUNOPLANT for Newly Diagnosed Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT06376526"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/immunoplant-nct06376526"}